Takeda Pharmaceutical

$15.18
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.45 (-2.88%) Today
$0.00 (0.00%) As of 8:00 PM EDT after-hours

Why Robinhood?

You can buy or sell TAK and other stocks, options, ETFs, and crypto commission-free!

About TAK

Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It operates through the following segments: Prescription Drug, Consumer Healthcare, and Other. Read More The Prescription Drugs segment includes the manufacture and sale of pharmaceutical products. The Consumer Healthcare segment includes the manufacture and sale of OTC drugs and quasi-drugs. The Other segment includes manufacture and sale of reagents, clinical diagnostics, and chemical products. The company was founded by Takeda Chobei on June 12, 1781 and is headquartered in Osaka, Japan.

Employees
49,578
Headquarters
Osaka, Osaka
Founded
1781
Market Cap
48.13B
Price-Earnings Ratio
Dividend Yield
2.65
Average Volume
3.30M
High Today
$15.35
Low Today
$15.06
Open Price
$15.35
Volume
1.47M
52 Week High
$20.93
52 Week Low
$12.43

Collections

TAK News

Reuters18h

BRIEF-Takeda Receives Positive CHMP Opinion For Adcetris, For Previously Untreated Systemic Anaplastic Large Cell Lymphoma

March 31 (Reuters) - Takeda Pharmaceutical Co Ltd: * TAKEDA RECEIVES POSITIVE CHMP OPINION FOR ADCETRIS IN COMBINATION WITH CHP FOR TREATMENT OF ADULT PATIENTS
11
ReutersMar 26

BRIEF-Evox Therapeutics And Takeda Sign Multi-Target Rare Disease Collaboration

March 26 (Reuters) - Takeda Pharmaceutical Co Ltd: * EVOX THERAPEUTICS AND TAKEDA SIGN MULTI-TARGET RARE DISEASE COLLABORATION * EVOX THERAPEUTICS LTD - WILL
90
ReutersMar 25

EU says Johnson & Johnson's deal for Takeda patch may harm competition

FILE PHOTO: The company logo for Johnson & Johnson is displayed on a screen to celebrate the 75th anniversary of the company's listing at the New York Stock Exc
163

TAK Earnings

$0.00
$0.39
$0.79
$1.18
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Estimated
$0.43 per share
Actual
Expected May 14, Pre-Market

People Also Bought

You May Also Like

Robinhood Snacks newsletters and podcasts reflect the opinions of only the authors who are associated persons of Robinhood Financial LLC and do not reflect the views of Robinhood Markets, Inc. or any of its subsidiaries or affiliates. They are meant for informational purposes only, are not intended to serve as a recommendation to buy or sell any security in a self-directed Robinhood account or any other account, and are not an offer or sale of a security. They are also not research reports and are not intended to serve as the basis for any investment decision. Any third-party information provided therein does not reflect the views of Robinhood Markets, Inc., Robinhood Financial LLC, or any of their subsidiaries or affiliates. All investments involve risk and the past performance of a security or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit or protect against loss. There is always the potential of losing money when you invest in securities or other financial products. Investors should consider their investment objectives and risks carefully before investing. The price of a given security may increase or decrease based on market conditions and customers may lose money, including their original investment. Robinhood Financial LLC, member FINRA/SIPC.

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.